Press release summary
AUSTIN, Texas โ Pattern Bioscience said Nov. 17 that five U.S. clinical microbiology laboratories have begun evaluating its investigational Pneumonia ID/AST Panel through the companyโs Early Evaluation Program.
The participating laboratories will assess workflow integration and usability and provide feedback ahead of a planned commercial introduction. Pattern expects additional sites to join the program. Results produced during the evaluations will not be used for patient management.
The panel runs on Patternโs single-cell microbiology platform and is designed to detect and identify bacteria and perform phenotypic antimicrobial susceptibility testing directly from lower respiratory tract specimens. Pattern says the approach is intended to return results in hours rather than the two to four days often required for conventional culture. The panel has received FDA Breakthrough Device designation but has not been cleared or approved by the agency.
Why it matters: Direct-from-specimen identification and susceptibility testing could help laboratories shorten pneumonia workups and provide earlier evidence for antibiotic selection. The evaluation program is also an important operational test of specimen handling, staffing, connectivity and integration with existing microbiology workflows. The announcement is not a performance study or regulatory authorization, so laboratories should wait for validated clinical data and FDA review before considering patient-care use.







Leave a Reply